Phesi Q1 2024 Business Update

Date: 05. 08. 2024

Phesi has had a strong start to the year in recognition of the role AI is playing in transforming clinical development – from simulating trials, from patient profiling, protocol design and investigator site selection, to reducing patient burden and accelerating the approval of new therapeutics.

The growing trend of using AI in clinical development topped the agenda at three major industry forums Phesi has attended so far this year: JP Morgan’s Annual Healthcare Conference in San Franciso, SCOPE in Florida and the Chief Medical Officer Summit in Boston. As part of an expert panel at CMOS with Leonardo Faoro at Quanta Therapeutics and Steven Zelenkofske at SLZ Consulting, our President Gen Li discussed how Phesi uses AI to help biotech and pharma companies design more effective trials and enhance investigator selection. Watch the discussion here.

Q1 2024 has seen a number of key milestones, including the launch of the second edition of our Digital Patient Profile Catalogue created using Phesi’s Trial Accelerator™ platform which now contains global contextualized data from 108 million patients. Covering 12 oncology profiles and 22 other prevalent diseases, Digital Patient Profiles help sponsors make data-led decisions in trial planning, design and execution. 

Phesi’s global expansion continues including several strategic hires. Earlier this year, Nate Collins joined our East-coast US team as Director of Client Partnerships, bringing more than 10 years experience in sales and strategic account management and a strong track record solving client needs in data analytics and life sciences, having previously worked at Informa. Data scientist Angela Perkovic joined our team in Europe serving our growing client base. 

As we continue to support our partners in disrupting clinical development and adopting new models using Digital Patient Profiles, Digital Twins and Digital Trial Arms to bring faster treatments to patients, we are delighted that Merck KGaA’s Tepmetko was approved by the US Food and Drug Administration (FDA) in February. Phesi’s data and insights helped support the development of this first and once-daily MET inhibitor for patients with metatastic non-small cell lung cancer (NSCLC).

In addition we are pleased to have successfully supported two different companies working in the ultra rare disease space of CDKL5 and GRIN Gain of Function.

Next stop on the Phesi roadshow is the ASCO general meeting in Chicago, May 31-4 June 2024, the world’s largest oncology meeting known for shaping new standards of care. Phesi will be  showcasing how our Trial Accelerator platform delivers smarter trials and faster cures in complex disease areas. 

Related news
05. 14. 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance Read more
02. 12. 2024
Phesi announces AI-driven Trial Accelerator™ hits critical milestone with data from 100 million patients Read more
01. 16. 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year Read more
10. 15. 2023
Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster Read more
09. 07. 2023
Phesi and Krystelis collaborate to launch new Diversity, Equity, and Inclusion Data Service for clinical development Read more
07. 14. 2023
Depression now one of the top five most studied disease areas in clinical development, finds new Phesi global analysis Read more